Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.
Contact
c/- Perks, 81 Flinders Street
Level 8
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 136.80 | -1.69% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,841.38 | 509.55 | -1.23% |
| FTSE 100 | 8,542.56 | 46.57 | 0.55% |
| HKSE | 23,462.65 | 319.49 | -1.34% |
| NASDAQ | 17,332.59 | 315.86 | -1.79% |
| Nikkei 225 | 36,790.03 | 3.08 | -0.01% |
| NZX 50 Index | 12,209.05 | 201.92 | -1.63% |
| S&P 500 | 5,525.79 | 73.51 | -1.31% |
| S&P/ASX 200 | 7,749.10 | 141.00 | -1.79% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |